vs
Brookfield Infrastructure Corp（BIPC）与爵士制药（JAZZ）财务数据对比。点击上方公司名可切换其他公司
爵士制药的季度营收约是Brookfield Infrastructure Corp的1.4倍（$1.2B vs $866.0M），爵士制药净利率更高（17.0% vs -35.7%，领先52.7%），爵士制药同比增速更快（10.1% vs -4.6%）
布鲁克菲尔德基础设施合伙公司是一家公开上市的有限合伙企业，总部位于加拿大多伦多，核心业务为在全球范围内开展基础设施资产的收购、运营与管理，在全球基础设施投资领域拥有深厚的行业积累与较强的市场影响力。
爵士制药是一家全球性生物制药企业，核心业务聚焦肿瘤学与神经科学两大领域，2003年在美国加利福尼亚州成立，当前总部坐落于爱尔兰首都都柏林。
BIPC vs JAZZ — 直观对比
营收规模更大
JAZZ
是对方的1.4倍
$866.0M
营收增速更快
JAZZ
高出14.7%
-4.6%
净利率更高
JAZZ
高出52.7%
-35.7%
损益表 — Q2 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $866.0M | $1.2B |
| 净利润 | $-309.0M | $203.5M |
| 毛利率 | 65.0% | — |
| 营业利润率 | 62.7% | 21.2% |
| 净利率 | -35.7% | 17.0% |
| 营收同比 | -4.6% | 10.1% |
| 净利润同比 | -148.1% | 6.5% |
| 每股收益（稀释后） | — | $3.34 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIPCJAZZ
| Q4 25 | — | $1.2B | ||
| Q3 25 | — | $1.1B | ||
| Q2 25 | $866.0M | $1.0B | ||
| Q1 25 | — | $897.8M | ||
| Q4 24 | — | $1.1B | ||
| Q3 24 | — | $1.1B | ||
| Q2 24 | $908.0M | $1.0B | ||
| Q1 24 | — | $902.0M |
净利润BIPCJAZZ
| Q4 25 | — | $203.5M | ||
| Q3 25 | — | $251.4M | ||
| Q2 25 | $-309.0M | $-718.5M | ||
| Q1 25 | — | $-92.5M | ||
| Q4 24 | — | $191.1M | ||
| Q3 24 | — | $215.1M | ||
| Q2 24 | $643.0M | $168.6M | ||
| Q1 24 | — | $-14.6M |
毛利率BIPCJAZZ
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 65.0% | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 63.8% | — | ||
| Q1 24 | — | — |
营业利润率BIPCJAZZ
| Q4 25 | — | 21.2% | ||
| Q3 25 | — | 5.1% | ||
| Q2 25 | 62.7% | -65.6% | ||
| Q1 25 | — | -6.2% | ||
| Q4 24 | — | 17.5% | ||
| Q3 24 | — | 24.7% | ||
| Q2 24 | 61.9% | 19.5% | ||
| Q1 24 | — | 7.3% |
净利率BIPCJAZZ
| Q4 25 | — | 17.0% | ||
| Q3 25 | — | 22.3% | ||
| Q2 25 | -35.7% | -68.7% | ||
| Q1 25 | — | -10.3% | ||
| Q4 24 | — | 17.6% | ||
| Q3 24 | — | 20.4% | ||
| Q2 24 | 70.8% | 16.5% | ||
| Q1 24 | — | -1.6% |
每股收益（稀释后）BIPCJAZZ
| Q4 25 | — | $3.34 | ||
| Q3 25 | — | $4.08 | ||
| Q2 25 | — | $-11.74 | ||
| Q1 25 | — | $-1.52 | ||
| Q4 24 | — | $2.97 | ||
| Q3 24 | — | $3.42 | ||
| Q2 24 | — | $2.49 | ||
| Q1 24 | — | $-0.23 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.2B | $1.4B |
| 总债务越低越好 | — | $5.4B |
| 股东权益账面价值 | $2.2B | $4.3B |
| 总资产 | $23.9B | $11.7B |
| 负债/权益比越低杠杆越低 | — | 1.24× |
8季度趋势，按日历期对齐
现金及短期投资BIPCJAZZ
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.3B | ||
| Q2 25 | $1.2B | $1.2B | ||
| Q1 25 | — | $1.9B | ||
| Q4 24 | — | $2.4B | ||
| Q3 24 | — | $2.2B | ||
| Q2 24 | $466.0M | $1.4B | ||
| Q1 24 | — | $1.4B |
总债务BIPCJAZZ
| Q4 25 | — | $5.4B | ||
| Q3 25 | — | $5.4B | ||
| Q2 25 | — | $5.4B | ||
| Q1 25 | — | $5.4B | ||
| Q4 24 | — | $6.1B | ||
| Q3 24 | — | $6.1B | ||
| Q2 24 | — | $5.7B | ||
| Q1 24 | — | $5.7B |
股东权益BIPCJAZZ
| Q4 25 | — | $4.3B | ||
| Q3 25 | — | $4.0B | ||
| Q2 25 | $2.2B | $3.7B | ||
| Q1 25 | — | $4.2B | ||
| Q4 24 | — | $4.1B | ||
| Q3 24 | — | $4.2B | ||
| Q2 24 | $3.5B | $3.8B | ||
| Q1 24 | — | $3.7B |
总资产BIPCJAZZ
| Q4 25 | — | $11.7B | ||
| Q3 25 | — | $11.4B | ||
| Q2 25 | $23.9B | $10.9B | ||
| Q1 25 | — | $11.5B | ||
| Q4 24 | — | $12.0B | ||
| Q3 24 | — | $12.3B | ||
| Q2 24 | $23.7B | $11.4B | ||
| Q1 24 | — | $11.3B |
负债/权益比BIPCJAZZ
| Q4 25 | — | 1.24× | ||
| Q3 25 | — | 1.35× | ||
| Q2 25 | — | 1.45× | ||
| Q1 25 | — | 1.29× | ||
| Q4 24 | — | 1.49× | ||
| Q3 24 | — | 1.47× | ||
| Q2 24 | — | 1.52× | ||
| Q1 24 | — | 1.54× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $478.0M | $362.5M |
| 自由现金流经营现金流 - 资本支出 | — | $345.8M |
| 自由现金流率自由现金流/营收 | — | 28.9% |
| 资本支出强度资本支出/营收 | — | 1.4% |
| 现金转化率经营现金流/净利润 | — | 1.78× |
| 过去12个月自由现金流最近4个季度 | — | $1.3B |
8季度趋势，按日历期对齐
经营现金流BIPCJAZZ
| Q4 25 | — | $362.5M | ||
| Q3 25 | — | $474.6M | ||
| Q2 25 | $478.0M | $88.9M | ||
| Q1 25 | — | $429.8M | ||
| Q4 24 | — | $398.6M | ||
| Q3 24 | — | $398.7M | ||
| Q2 24 | $511.0M | $331.4M | ||
| Q1 24 | — | $267.2M |
自由现金流BIPCJAZZ
| Q4 25 | — | $345.8M | ||
| Q3 25 | — | $459.4M | ||
| Q2 25 | — | $75.9M | ||
| Q1 25 | — | $415.9M | ||
| Q4 24 | — | $385.3M | ||
| Q3 24 | — | $388.0M | ||
| Q2 24 | — | $324.3M | ||
| Q1 24 | — | $260.3M |
自由现金流率BIPCJAZZ
| Q4 25 | — | 28.9% | ||
| Q3 25 | — | 40.8% | ||
| Q2 25 | — | 7.3% | ||
| Q1 25 | — | 46.3% | ||
| Q4 24 | — | 35.4% | ||
| Q3 24 | — | 36.8% | ||
| Q2 24 | — | 31.7% | ||
| Q1 24 | — | 28.9% |
资本支出强度BIPCJAZZ
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 1.3% | ||
| Q2 25 | — | 1.2% | ||
| Q1 25 | — | 1.5% | ||
| Q4 24 | — | 1.2% | ||
| Q3 24 | — | 1.0% | ||
| Q2 24 | — | 0.7% | ||
| Q1 24 | — | 0.8% |
现金转化率BIPCJAZZ
| Q4 25 | — | 1.78× | ||
| Q3 25 | — | 1.89× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 2.09× | ||
| Q3 24 | — | 1.85× | ||
| Q2 24 | 0.79× | 1.97× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIPC
暂无分部数据
JAZZ
| Xywav | $465.5M | 39% |
| Total Oncology | $337.8M | 28% |
| Rylaze Enrylaze | $108.2M | 9% |
| Zepzelca | $90.4M | 8% |
| Product And Services Royalties And Contract Revenue | $65.5M | 5% |
| High Sodium AG Oxybate Product Royalty Revenue | $55.7M | 5% |
| Xyrem | $37.8M | 3% |
| Vyxeos | $34.7M | 3% |
| Ziihera | $8.5M | 1% |
| Other Products | $2.8M | 0% |
| Sativex | $1.5M | 0% |
